Ucb S.A. (Belgium) has DMF or CEP filings on record for 1 active ingredient. No FDA recall, Warning Letter or Form 483 record is linked to it, which is not proof that none exists.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Ucb S.A.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/ucb-s-a

Overview

Ucb S.A. is a global biopharmaceutical company headquartered in Belgium. It is dedicated to the discovery and development of innovative medicines and solutions for people living with severe diseases in immunology and neurology. Ucb aims to improve the quality of life for patients and is focused on creating value for its patients and stakeholders.

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Ucb S.A. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Ucb S.A. in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.

For suppliers

Is this Ucb S.A.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.